Cancer Treatment Reviews
Volume 26, Issue 2 , Pages 103-125 , April 2000

Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives

References 

  1. Millis RR, Handy AM, Oberman HA. The Breast. Diagnostic Surgical Pathology, 3rd Ed. New York: Lippincott William & Wilkins Ed; 1999; p. 319–385
  2. Frykberg ER, Santiago F, Betsill WL. Lobular carcinoma in situ of the breast. Surg Gynecol Obstet. 1987;164:285–301
  3. Soran A, Vogel VG. Optimal management of primary breast cancer. Breast J. 1999;5:81–93
  4. Lagios MD. Duct carcinoma in situ: pathology and treatment. Surg Clin North Am. 1990;70:853–871
  5. Cheatle GL. Early recognition of cancer of the breast. BMJ. 1906;1:1205–1210
  6. Warren JC. Abnormal involution of the mammary gland with its treatment byoperation. Am J Med Sci. 1907;134:521–535
  7. Bloodgood JC. Border-line breast tumors. Ann Surg. 1931;93:235–249
  8. Bloodgood JC. Comedo-carcinoma (or comedo-adenoma) of the female breast. Am J Cancer. 1934;22:842–853
  9. Cornil, V. Les tumeurs du Sein. Paris, Librairie Germes Bailliers, 1908
  10. Ewing, J. Neoplastic Diseases. Philadelphia, WB Saunders, 1919
  11. Foote FW, Stewart FW. Lobular carcinoma in situ: a rare form of mammary cancer. Am J Pathol. 1941;17:491–495
  12. Broders AC. Carcinoma in situ contrasted with benign penetrating epithelium. JAMA. 1932;99:1670–1674
  13. Gillis DA, Dockerty MB, Clagettt OT. Preinvasive intraductal carcinoma of the breast. Surg Gynecol Obstet. 1960;110:555–562
  14. Peters TG, Donegan WL, Burg EA. Minimal invasive breast cancer: a clinical appraisal. Ann Surg. 1977;186:704–710
  15. Frazier TG, Copeland EM, Gallager HS. Prognosis and treatment in minimal breast cancer. Am J Surg. 1977;133:697–701
  16. Muir R. The evolution of carcinoma in the mamma. J Pathol Bacteriol. 1941;52:155–172
  17. Wellings RR, Jensen HM, Marcum RG. An atlas of subgross pathology of human breast with special reference for possible precancerous lesions. J Natl Cancer Instit. 1975;55:231–273
  18. Farrow JH. Current concepts in the detection and treatment of the earliest of early breast cancers. Cancer. 1970;25:468–477
  19. Rosner D, Bedwani RN, Vana J. Noninvasive breast carcinoma: results of a national survey by the American College of Surgeons. Ann Surg. 1980;192:139–147
  20. Garfinkel L, Boring CC, Heath CW. Changing trends. An overview of breast cancer incidence and mortality. Cancer. 1994;74:222–227
  21. Feuer EJ, Wun LM. How much of the recent rise in breast cancer incidence can be explained by increases in mammography utilization? A dynamic population model approach. Am J Epidemiol. 1992;136:1423–1436
  22. Ernster VL, Barclay J, Kerlikowske K. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA. 1996;275:913–918
  23. Simon MS, Lemanne D, Schwartz AG. Recent trends in the incidence of in situ and invasive breast cancer in the Detroit metropolitan area (1975–1988). Cancer. 1993;71:769–774
  24. Kessler LG, Feuer EJ, Brown ML. Projections of the breast cancer burden to U.S. women: 1900–2000. Prev Med. 1991;20:170–182
  25. Surveillance epidemiology and end-results (SEER) program public use C.D-R.O.M. (1973–1992).. Bethesda, Md: National Cancer Institute, DCPC, Surveillance Program, Cancer Statistics Branch; July 1995;
  26. Osteen RT. Breast cancer. In:  Steele GD,  Winchester DP,  Menck HR editor. National Cancer Data Base Annual Review of Patient Care. Atlanda, GA: Americal Cancer Society; 1993;p. 10–19
  27. Nystrom L, Rutqvist LE, Wall S. Breast cancer screening with mammography: Overview of Swedish randomized trials. Lancet. 1993;341:973–978
  28. Kerlikowske K, Grady D, Barclay J. Positive predictive value of screening mammography by age and family history of breast cancer. JAMA. 1993;270:2444–2450
  29. Lagios MD. Duct carcinoma in situ: biological implications for clinical practice. Sem Oncol. 1996;23:6–11
  30. Papatestas AE, Hermann D, Hermann G. Surgery for nonpalbable breast lesions. Arch Surg. 1990;125:399–402
  31. Vezeridis MP, Bland KI. Management of ductal carcinoma in situ. Surg Oncol. 1994;3:309–325
  32. Ringberg A, Andersson I, Aspegren K. Breast carcinoma in situ in 167 women – incidence, mode of presentation, therapy, and follow-up. Eur J Surg Oncol. 1991;17:466–476
  33. Robinson EK, Hunt KK. Noninvasive breast cancer. In:  Feig BW,  Berger DH,  Fuhrman GM editor. The MD Anderson Surgical Oncology Handbook. Philadelphia: Lippincott Williams & Wilkins Ed,; 1999;p. 1–12
  34. Camus MG, Joshi MG, Mackarem G. Ductal carcinoma in situ of the male breast. Cancer. 1994;74:1289–1293
  35. Bartow SA, Pathak DR, Black WC. Prevalance of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer: a forensic autopsy study. Cancer. 1987;60:2751–2760
  36. Nielsen WM, Jensen J, Andersen J. Precancerous and cancerous breast lesions during lifetime and at autopsy: a study of 83 women. Cancer. 1984;54:612–615
  37. Alpers CE, Wellings SR. The prevalence of carcinoma in situ in normal and cancer-associated breasts. Hum Pathol. 1985;16:796–807
  38. Bhathal PS, Brown RW, Lesueur GC. Frequency of benign and malignant breast lesions in 207 consecutive autopsies in Australian women. Br J Cancer. 1985;51:271–278
  39. Nielsen M, Thomsen JL, Primdahl S. Breast Cancer and atypia among young and middle-aged women: a study of 110 medocolegal autopsies. Br J Cancer. 1987;56:814–819
  40. Page DL, Dupont WD, Rogers LW. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer. 1982;49:751–758
  41. Page DL, Dupont WD, Rogers LW. Continued local recurrence of carcinoma 15–25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer. 1995;76:1197–1200
  42. Rosen PP, Braun DW, Kinne DE. The clinical significance of pre-invasive breast carcinoma. Cancer. 1980;46:919–925
  43. Betsill WL, Rosen PP, Lieberman PH. Intraductal carcinoma: long-term follow-up after treatment by biopsy alone. JAMA. 1978;239:1863–1867
  44. Eusebi V, Feudale E, Foschini MP. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol. 1994;11:223–235
  45. Schnitt SJ, Silen W, Sadowsky NL. Ductal carcinoma in situ (intraductal carcinoma) of the breast-current concepts. N Engl J Med. 1988;318:898–903
  46. Barth A, Brenner J, Guiliano AE. Current management of ductal carcinoma in situ. West J Med. 1995;163:360–366
  47. Wellings SR, Jensen HM. On the origin and progression of ductal carcinoma of the human breast. J Natl Cancer Instit. 1973;50:1111–1116
  48. Fisher ER. The impact of pathology on the biologic, diagnostic, prognostic, and therapeutic considerations in breast cancer. Surg Clin North Am. 1984;64:1073–1093
  49. Frykberg ER, Masood S, Copeland EM, Bland KI. Ductal carcinoma in situ of the breast. Surg Gynecol Obstet. 1993;177:425–440
  50. Rosen PP. Lobular carcinoma in situ and intraductal carcinoma of the breast. Monogr Pathol. 1984;25:59–105
  51. Jones EL, Codling BW, Oates GD. Necrotic intraductal breast carcinomas simulating inflammatory lesions. J Pathol. 1973;110:101–103
  52. Egan RL, McSweeney MB, Sewell CW. Intramammary calcifications without an associated mass in benign and malignant diseases. Ragiology. 1980;137:1–7
  53. Tavassoli FA. Ductal intraepithelial neoplasia. In:  Tavassoli FA editors. Pathology of the Breast, 2nd Ed. Stamford, CT: Appleton & Lange; 1999;p. 205–323
  54. Fisher ER, Sass R, Fisher B. Pathologic findings from the National Surgical Adjuvant Project (protocol 6), I, intraductal carcinoma (DCIS). Cancer. 1986;57:197–208
  55. Schitt SJ, Connolly JL, Tavassoli FA. Interobserver reproductibility in the diagnosis of ductal proliferative breast lesions using standarized criteria. Am J Surg Pathol. 1992;16:1133–1143
  56. Mariuzzi GM, Mariuzzi L, Mombello A. Quantitative study of ductal breast cancer progression: morphometric evaluation of phenotypical changes occurring in benign and preinvasive epithelial lesions. Pathol Res Pract. 1994;190:1056–1065
  57. Lennington WJ, Jensen RA, Dalton LW. Ductal carcinoma in situ of the breast. Heterogeneity of individual lesions. Cancer. 1994;73:118–124
  58. Patchefsky AS, Schwartz GF, Finkelstein SD. Heterogeneity of intraductal carcinoma of the breast. Cancer. 1989;63:731–741
  59. Winchester DP, Strom EA. Standards for diagnosis and management of ductal carcinoma in situ (DCIS) of the breast. CA-Cancer J Clin. 1998;48:108–128
  60. Frykberg ER, Bland KI. In situ breast carcinoma. In:  Cameron JL editors. Advances in Surgery. St Louis: Mosby Year Book Medical Publishers; 1993;p. pp 29–72
  61. Schartz GF, Patchefsky AS, Finklestein SD. Nonpalpable in situ ductal carcinoma of the breast. Arch Surg. 1989;124:29–32
  62. Schwartz GF, Patchefsky AS, Finklestein SD. Subclinical ductal carcinoma in situ of the breast. Treatment by local excision and surveillance alone. Cancer. 1992;70:2468–2474
  63. Lagios MD, Margolin FR, Westdahl PR. Mammographically detected duct carcinoma in situ – frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer. 1989;63:618–624
  64. Solin LJ, Yeh IT, Kurtz J. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation – correlation of pathologic parameters with outcome of treatment. Cancer. 1993;71:2532–2542
  65. Baird RM, Worth A, Hislop G. Recurrence after lumpectomy for comedo-type intraductal carcinoma of the breast. Am J Surg. 1990;159:479–481
  66. Meyer JS. Cell kinetics of histologic variants of in situ breast carcinoma. Breast Cancer Res Treat. 1986;7:171–180
  67. Aasmundstad TA, Haugen OA. DNA ploidy in intraductal breast carcinomas. Eur J Cancer. 1990;26:956–959
  68. Nielsen KV, Blichert-Toft MD, Andersen JA. Chromosome analysis of in situ breast cancer. Acta Oncol. 1989;28:919–922
  69. Bartkova J, Barnes DM, Millis RR. Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. Hum Pathol. 1990;21:1164–1167
  70. Poller DN, Roberts EC, Bell JA. p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum Pathol. 1993;24:463–468
  71. Allred DC, Clark GM, Molin R. Overexpression of HER-2/neu and its relationship with daily prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992;23:974–979
  72. Killeen JL, Namiki H. DNA analysis of ductal carcinoma in situ of the breast: a comparison with histologic features. Cancer. 1991;58:2602–2607
  73. Griffin A, Fraze RC. Treatment of intraductal breast cancer – noncomedo type. Am Surg. 1993;59:106–109
  74. Fonseca R, Hartmann LC, Petersen IA. Ductal carcinoma in situ of the breast. Ann Intern Med. 1997;127:1013–1022
  75. Lagios MD, Westdahl PR, Margolin FR. Duct carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer. 1982;50:1309–1314
  76. Rosen PP, Senie R, Schottenfeld D, Ashikari R. Noninvasive breast carcinoma. Frequency of unsuspected invasion and implications for treatment. Ann Surg. 1979;189:377–382
  77. Fisher ER, Leeming R, Anderson S. Conservative management of intraductal carcinoma (DCIS) of the breast. Collaborating NSABP investigators. J Surg Oncol. 1991;47:139–147
  78. Holland R, Veiling SHJ, Mravunac M. Histologic multifocality of Tis, T1–2 breast carcinoma. Cancer. 1985;56:979–990
  79. Fentiman IS, Fagg N, Millis RR. In situ ductal carcinoma of the breast: Implications of disease pattern and treatment. Eur J Surg Oncol. 1986;12:261–266
  80. Petersee JL, Gelderman WH, van Dongen JA. Ductal carcinoma in situ of the breast: a clinicopathological analysis of 70 cases. Ned Tijdschr Geneeskd. 1986;130:308–310
  81. Webber BL, Heise H, Neifeld JP, Costa J. Risk of subsequent contralateral breast carcinoma in a population of patients with in situ breast carcinoma. Cancer. 1981;47:2928–2932
  82. Catalioti L, Distante V, Ciatto S. Intraductal breast cancer: review of 183 consecutive cases. Eur J Cancer. 1992;28A:917–920
  83. Habel LA, Moe RE, Daling JR. Risk of controlateral breast cancer among women with carcinoma in situ of the breast. Ann Surg. 1997;225:69–75
  84. Fisher ER, Fisher B, Sass R. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project (Protocol No 4): XI. Bilateral breast cancer. Cancer. 1984;54:3002–3011
  85. Gallagher HS, Martin JE. An orientation to the concept of minimal breast cancer. Cancer. 1971;53:681–684
  86. Wong JH, Kopald KH, Morton DL. The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer. Arch Surg. 1990;125:1298–1302
  87. Bose S, Lesser MZ, Norton L. Immunophenotype of intraductal carcinoma. Arch Pathol Lab Med. 1996;120:81–85
  88. Somerville JE, Clarke LA, Biggart JD. c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma. J Clin Pathol. 1992;45:16–20
  89. Douglas-Jones AG, Navabi H, Morgan JM. Immunoreactive p53 and metallothionein expression in DCIS of the breast. Virchows Arch [A]. 1997;430:373–379
  90. Walker RA, Dearing SJ, Lane DP. Expression of p53 protein in infiltrating and in-situ breast carcinomas. J Pathol. 1991;165:203–211
  91. Munn KE, Walker RA, Menasce L, Varley JM. Allelic imbalance in the region of the BRCA1 gene in ductal carcinoma in situ of the breast. Br J Cancer. 1996;73:636–639
  92. Weinstat-Saslow D, Merino MJ, Manrow RE. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med. 1995;1:1257–1260
  93. Goedde TA, Frykberg ER, Crump JM. The impact of mammography on breast biopsy. Am Surg. 1992;58:661–666
  94. Evans A, Pinder S, Wilson R. Ductal carcinoma of the breast: correlation between mammographic and pathologic findings. AJR Am J Roentgenol. 1994;162:1307–1311
  95. Knutzen AM, Gisvold JJ. Likelihood of malignant disease for various categories of mammographically detected, nonpalpable breast lesions. Mayo Clin Proc. 1993;68:454–460
  96. Bassett LW. Mammographic analysis of calcifications. Radiol Clin North Am. 1992;30:93–105
  97. Holland R, Hendriks JH. Microcalcifications associated with ductal carcinoma in situ: mammographic-pathologic correlation. Sem Diagn Pathol. 1994;11:181–192
  98. Stomper PC, Connolly JL. Ductal carcinoma in situ of the breast; correlation between mammographic calcification and tumor subtype. AJR Am J Roentgenol. 1992;159:483–485
  99. Holland R, Hendricks JHCL, Verbeek ALM. Extent, distribution, and mammographic histologic correlations of breast ductal carcinoma in situ. Lancet. 1990;335:519–522
  100. Ikeda DM, Andersson I. Ductal carcinoma in situ: atypical mammographic appearances. Radiology. 1989;172:661–666
  101. Stomper PC, Connolly JL, Meyer JE. Clinically occult ductal carcinoma in situ detected with mammography: analysis of 100 cases with radiologic-pathologic correlation. Radiology. 1989;172:235–241
  102. Withelm MC, DeParedes ES, Pope T. The changing mammogram. A primary indication for needle localization biopsy. Arch Surg. 1986;121:1311–1314
  103. Lang NP, Talbert GE, Shewmanke KB. The current evaluation of nonpalpable breast lesions. Arch Surg. 1987;122:1389–1391
  104. Sakorafas, G. H. Farley, D. R. Portales, A. Conservative-surgery in breast cancer. Lagos Medical Publications, Athens, 1999
  105. Sakorafas GH. Breast Cancer. Athens: Lagos Medical Publications; 1999; p. 110
  106. Roth WD, von Smitten K, Heikkila P. Automated stereotactic core needle biopsy of microcalcifications with correlation to surgical biopsy. Acta Radiol. 1999;40:390–393
  107. Rebner M, Chesbrough R, Gregory N. Initial experience with the advanced breast biopsy instrumentation device. AJR Am J Roentgenol. 1999;173:221–226
  108. Ashikari R, Hadju SI, Robbins GF. Intraductal carcinoma of the breast. Cancer. 1971;28:1182–1187
  109. Westbrook KC, Gallager HS. Intraductal carcinoma of the breast: a comparative study. Am J Surg. 1975;130:667–670
  110. Carter D, Smith RRL. Carcinoma in situ of the breast. Cancer. 1977;40:1189–1193
  111. Brown PW, Silverman J, Owens E. Intraductal “noninfiltrating” carcinoma of the breast. Arch Surg. 1976;111:1063–1067
  112. Silverstein MJ, Lagios MD, Craig PH. A prognostic index for ductal carcinoma in situ of the breast. Cancer. 1996;77:2267–2274
  113. Sneige N, McNeese MD, Atkinson EN. Ductal carcinoma in situ treated with lumpectomy and irradition. Hum Pathol. 1995;26:642–649
  114. Arnesson LG, Smeds S, Fagerberg G. Follow-up of two treatment modalities for ductal carcinoma in situ of the breast. Br J Surg. 1989;76:672–675
  115. McCormick B, Rosen PP, Kinne D. Duct carcinoma in situ of the breast; an analysis of local control after conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 1991;21:289–292
  116. Solin LJ, McCormick B, Recht A. Mammographically detected, clinically occult ductal carcinoma in situ (intraductal carcinoma) treated with breast conserving surgery and definitive breast irradiation. Cancer J Sci Am. 1996;2:158–165
  117. Schnitt SJ, Connolly JL. Processing and evaluation of breast excision specimens: a clinically-oriented approach. Am J Clin Pathol. 1992;98:125–137
  118. Fowble B, Hanlon AL, Fein DA. Results of conservative surgery and radiation for mammographically detected ductal carcinoma in situ (DCIS). Int J Radiat Oncol Biol Phys. 1997;38:949–957
  119. Sneige N, McNeese MD, Atkinson EN. Ductal carcinoma in situ treated with lumpectomy and irradiation: histopathologic analysis of 49 specimens with emphasis on risk factors and long-term results. Hum Pathol. 1995;26:642–649
  120. Fisher B, Costantino J, Redmont C. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med. 1993;328:1581–1586
  121. Kurtz JM, Jacquemier J, Torhorst J. Conservation therapy for breast cancers others than infiltrating ductal carcinoma. Cancer. 1989;63:1630–1635
  122. Kuske RR, Bean JM, Garcia DM. Breast conservation therapy for intraductal carcinoma of the breast. Int J Radiat Oncol Biol Phys. 1993;26:391–396
  123. Solin LJ, Kurtz J, Fourquet A. Fifteen-years of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol. 1996;14:754–763
  124. Bobrow LG, Happerfiled LC, Gregory WM. The classification of ductal carcinoma in situ and its association with biologic markers. Semin Diagn Pathol. 1994;12:199–207
  125. Crissman JD, Visscher DW, Kubus J. Image cytophotometricDNA analysis of atypical hyperplasias and intraductal carcinomas of the breast. Arch Pathol Lab Med. 1990;114:1249–1253
  126. Holland R, Peterse JL, Millis RR. Ductal carcinoma in situ: a proposal for new classification. Semin Diagn Pathol. 1994;11:167–180
  127. Van Zee PJ, Liberman L, McCormick B. Long-term follow-up of DCIS treated with breast conservation: effect of age and radiation,. Abstract Book, Society of Surgical Oncology, Atlanta, March 21–24, 1996. Arlington Heights IL: SSO; 1996;
  128. Bornstein BA, Recht A, Connolly JL. Results of treating ductal carcinoma in situ of the breast with conservative surgery and radiation therapy. Cancer. 1991;67:7–13
  129. Gump FE, Jicha DL, Ozzello L. Ductal carcinoma in situ (DCIS): a revised concept. Surgery. 1987;102:790–795
  130. Hiramatsu H, Bornstein BA, Recht A. Local recurrence after conservative surgery and radiation therapy for ductal carcinoma in situ: possible importance of family history. Cancer J Sci Am. 1995;1:55–61
  131. Vicini FA, Lacerna MD, Horwitz EM. Mammographically detected DCIS treated with breast conserving therapy: an analysis of clinical, pathologic, and treatment related factors affecting outcome. Int J Radiat Oncol Biol Phys. 1996;36:214 A
  132. Silverstein MJ, Poller DN, Waisman JR. Prognostic classification of breast ductal carcinoma in situ. Lancet. 1995;345:1147–1154
  133. Silverstein MJ, Lagios MD, Craig PH. The Van Nuys Prognostic Index for Ductal Carcinoma in Situ. Breast J. 1996;2:38–40
  134. Kinne DW, Petrek JA, Osborne MP. Breast carcinoma in situ. Arch Surg. 1989;124:33–36
  135. Ashikari R, Huvos AG, Snyder RE. Prospective study of non-infiltrating carcinoma of the breast. Cancer. 1977;39:435–439
  136. Silverstein MJ, Barth A, Poller DN. Ten-years results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur J Cancer. 1995;31A:1425–1427
  137. Schuh ME, Nemoto T, Penetrante RB. Intraductal carcinoma. Analysis of presentation, pathologic findings, and outcome of disease. Arch Surg. 1986;121:1303–1307
  138. Sunshine JA, Moseley HS, Fletcher WS. Breast carcinoma in situ. A retrospective review of 112 cases with a minimum 10 year follow-up. Am J Surg. 1985;150:44–51
  139. VonRueden DG, Wilson RE. Intraductal carcinoma of the breast. Surg Gynecol Obstet. 1984;158:105–111
  140. Ciatto, S. Bonardi, R. Cataliotti, L. et al., Intraductal breast carcinoma – review of a multicenter series of 350 cases. Coordinating center and writing committee of National Task Force for Breast Cancer, Italy, Tumori, 1990, 76, 552, 554
  141. Lagios MD. Pathologic features related to local recurrence following lumpectomy and irradiation. Semin Surg Oncol. 1992;8:122–128
  142. Solin LJ, Fowble BL, Schultz DJ. Definitive irradiation for intraductal carcinoma of the breast. Int J Radiat Oncol Biol Phys. 1990;19:843–850
  143. Silverstein MJ, Cohlan BF, Gierson ED. Ductal carcinoma in situ: 227 cases without microinvasion. Eur J Cancer. 1992;28(2–3):630–634
  144. Fisher B, Redmond C, Poisson R. Eight-year results of a randomized trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1989;320:822–828
  145. Haffty BG, Peschel RE, Papadopoulos D. Radiation therapy for ductal carcinoma in situ of the breast. Conn Med. 1990;54:482–484
  146. Solin LJ, Recht A, Fourquet A. Ten-years results of breast-conserving surgery and definitive irradiation for intraductal carcinoma (ductal carcinoma in situ) of the breast. Cancer. 1991;68:2337–2344
  147. Ray GR, Adelson J, Hayhurst E. Ductal carcinoma in situ of the breast: results of treatment by conservative surgery and definitive irradiation. Int J Radiat Oncol Biol Phys. 1994;28:105–111
  148. McCormick B, Rosen PP, Kinne DW. Ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys. 1990;19:132
  149. Stotter AT, McNeese M, Oswald MJ. The role of limited surgery with irradiation in primary treatment of ductal in situ breast cancer. Int J Radiat Oncol Biol Phys. 1990;18:283–287
  150. Zafrani B, Fourquet A, Vilcoq JR. Conservative management of intraductal breast carcinoma with tumorectomy and radiation therapy. Cancer. 1986;57:1299–1301
  151. Cutuli B, Tessier E, Piat J–M. Radical surgery and conservative treatment of duct carcinoma in situ of the breast. Eur J Cancer. 1992;28:649–654
  152. Recht A, Danoff BS, Solin LJ. Intraductal carcinoma of the breast: results of treatment with excision biopsy and irradiation. J Clin Oncol. 1985;3:1339–1343
  153. Choi WS, Parker BA, Pierce JP. Regional differences in the incidence and treatment of carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 1996;5:317–320
  154. Silverstein MJ, Waisman JR, Gierson ED. Radiation therapy for intraductal carcinoma. Is it an equal alternative?. Arch Surg. 1991;126:424–428
  155. Lagios MD. Ductal carcinoma in situ: controversies in diagnosis, biology, and treatment. Breast J. 1995;1:68–78
  156. Carpenter DP, Boulter PS, Cooke T, Gibbs NM. Management of screen detected ductal carcinoma in situ of the female breast. Br J Surg. 1989;76:564–567
  157. Graham MD, Lakhani S, ‘Gazet JC. Breast conserving surgery in the management of in situ breast carcinoma. Eur J Surg Oncol. 1991;17:258–264
  158. Gallagher WJ, Koerner FC, Wood WC. Treatment of intraductal carcinoma with limited surgery: long-term follow-up. J Clin Oncol. 1989;7:376–380
  159. Price P, Sinnett HD, Gusterson B. Duct carcinoma in situ: predictors of local recurrence and progression in patients treated by surgery alone. Br J Cancer. 1990;61:869–872
  160. Ottesen GL, Gravensen HP, Blichert-Toft M. Ductal carcinoma in situ of the female breast. Short-term results of a prospective national-wide study. The Danish Breast Cancer Cooperative Group. Am J Surg Pathol. 1992;16:1183–1196
  161. Tempe WJ, Jenkins M, Alexander F. Natural history of in situ breast cancer in a defined population. Ann Surg. 1989;210:653–657
  162. Salvadori B, Delledonne V, Rovini D. National Cancer Institute-Milan experience. In:  Silverstein MJ editors. Ductal Carcinoma in Situ of the Breast. Baltimore: Williams & Wilkins; 1997;p. 427–432
  163. Shreer I. Conservation therapy of DCIS without radiation. Breast Dis. 1996;9:27–36
  164. Sibbering DM, Blamey RW. Nottingham experience. In:  Silverstein MJ editors. Ductal Carcinoma in Situ of the Breast. Baltimore: Williams & Wilkins; 1997;p. 367–372
  165. Bellamy COC, McDonald C, Salter DM. Noninvasive ductal carcinoma of the breast. The relevance of histologic categorization. Hum Pathol. 1993;24:16–23
  166. Carlson RW, Goldstein LJ, Gradishar WJ. NCCN Breast Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Hunting). 1996;10:47–75
  167. Lagios MD, Page DL. A critical appraisal of NSABP – B 17, a randomized trial of irradiation of duct carcinoma in situ. Quartely Review. Current Perspectives in Breast Cancer. 1991;1
  168. Fisher ER, Costantino J, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) project B-17. Cancer. 1995;75:1310–1319
  169. Mamounas E, Fisher B, Dingam J. Effects of breast irradiation following lumpectomy in intraductal carcinoma (DCIS): Updated results from NSABP B-17. Proc Soc Surg Oncol. 1997;50:7
  170. Gilliland MD, Barton RM, Copeland EM. The implications of local recurrence of breast cancer as the first site of therapeutic failure. Ann Surg. 1983;197:284–287
  171. Ciatto S, Grazzini G, Iossa A. In situ ductal carcinoma of the breast – analysis of clinical presentation and outcome in 156 consecutive cases. Eur J Surg Oncol. 1990;16:224–229
  172. Silverstein MJ, Gierson ED, Golburn WJ. Axillary lymphadenectomy for intraductal carcinoma of the breast. Surg Gynecol Obstet. 1991;172:211–214
  173. Silverstein MJ, Rosser RJ, Gierson ED. Axillary lymph node dissection for intraductal breast carcinoma – is it indicated?. Cancer. 1987;59:1819–1824
  174. Balch CM, Singletary SE, Bland KI. Clinical decision-making in early breast cancer. Ann Surg. 1993;217:207–225
  175. Frykberg ER, Bland KI. Overview of the Biology and Management of Ductal Carcinoma in Situ of the Breast. Cancer. 1994;74:350–361
  176. Poller DN, Snead DR, Roberts EC. Estrogen receptor expression in ductal carcinoma in situ of the breast; relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein. Br J Cancer. 1993;68:156–161
  177. Bur ME, Zimarowski MJ, Schnitt SJ. Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer. 1992;69:1174–1181
  178. Malafa M, Chaudhuri B, Thomford NR. Estrogen receptors in ductal carcinoma in situ of the breast. Am Surg. 1990;56:436–439
  179. Chaudhuri B, Crist KA, Mucci S. Distribution of estrogen receptor in ductal carcinoma in situ of the breast. Surgery. 1993;113:134–137
  180. Powles TJ, Jones AC, Ashley SE. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat. 1994;31:73–82
  181. Cummings S, Norton L, Eckert S. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women: Two-year findings from the Multiple Outcomes of Raloxifene Evaluation Trial. Proc ASCO. 1998;17:
  182. Iornander T, Rutquist LE, Cedermark B. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet. 1989;1:117–120
  183. Fisher B, Costantino JP, Wickerham DL. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1371–1388
  184. Tavassoli FA. Infiltrating carcinoma: common and familiar special types. In:  Tavassoli FA editors. Pathology of the Breast, 2nd Ed. Stamford, CT: Appleton & Lange; 1999;p. 401–480
  185. Schnitt SJ, Connolly JL, Harris JR. Pathologic predictors of early local recurrences in stage I and II breast cancer treated by primary radiation therapy. Cancer. 1984;53:1049–1055
  186. Gelman R, Osteen RT, Schnitt SJ. Recurrence in the breast following conservative surgery and radiation therapy for early-stage breast cancer. Monogr Natl Cancer Instit. 1992;11:33–39
  187. Kurtz JM. Factors influencing the risk of local recurrence in the breast. Eur J Cancer. 1992;28:660–666
  188. Schnitt SJ, Abner A, Gelman R. The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy. Cancer. 1994;74:1746–1751
  189. Sakorafas, G. H. Tsiotou, A. G. Selection criteria for breast-conserving surgery. Eur J Surg
  190. Solin LJ, Kurtz J, Fourquet A. Fifteen year results of breast conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ (intraductal carcinoma) of the breast [abstract]. Proc Am Soc Clin Oncol. 1995;14:107
  191. Solin LJ, Fourquet A, McCormik B. Salvage treatment for local recurrence following breast-conserving surgery and definitive irradiation for ductal carcinoma in situ (intraductal carcinoma) of the breast. Int J Radiat Oncol Biol Phys. 1994;30:3–9

☆ 1This trial has since been published. See Firher B, Dignam J, Wolmark N et al. Tamoxifen in the treatment of intraductal breast cancer. National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet 1999;353: 1993–2000.

☆☆ 2Some authors have proposed larger tumor size (> 4 cm) as an indication for mastectomy (3, 143). However, the larger the tumour, the more difficult to achieve complete tumour removal with satisfactory cosmetic result

PII: S0305-7372(99)90149-4

doi: 10.1053/ctrv.1999.0149

Cancer Treatment Reviews
Volume 26, Issue 2 , Pages 103-125 , April 2000

Article Tools